Letters to the Editor
Vol. 15 No. 1 (2023): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: November 12, 2022
Accepted: November 26, 2022
Accepted: November 26, 2022
1197
Views
900
Downloads
381
HTML
Authors
n.
Downloads
Download data is not yet available.
Citations
Costa, L. J., & Usmani, S. Z. (2020). Defining and Managing High-Risk Multiple Myeloma: Current Concepts, Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw, 18(12), 1730-1737. Retrieved May 20, 2022, from https://jnccn.org/view/journals/jnccn/18/12/article-p1730.xml
Ikewaki J, Ogata M, Imamura T, Kohno K, Nakayama T, Kadota J. Development of hyperammonemic encephalopathy in patients with multiple myeloma may be associated with the appearance of peripheral blood myeloma cells. Leuk Lymphoma. 2009 Apr;50(4):667-9. doi: 10.1080/10428190902741489. PMID: 19373670.
Jaime Lora-Tamayo, Xavier Palom, José Sarrá, Oriol Gasch, Virginia Isern, Alberto Fernández de Sevilla, Ramón Pujol, Multiple Myeloma and Hyperammonemic Encephalopathy: Review of 27 Cases, Clinical Lymphoma and Myeloma, Volume 8, Issue 6, 2008, Pages 363-369, ISSN 1557-9190, https://doi.org/10.3816/CLM.2008.n.054.
Gertz MA, Buadi FK. Plasma cell leukemia. Haematologica. 2010;95(5):705-707. doi:10.3324/haematol.2009.021618
Howman R , Th akerer A , Pitman M , et al . Bortezomib, cyclophosphamide, and dexamethasone: highly eff ective for rapid reversal of myeloma-associated hyperammonemic encephalopathy . Leuk Lymphoma 2010 ; 51 : 2299 – 2302.
Amit Patel, Umeer Waheed, Stephen J. Brett, Amin Rahemtulla, Jane F. Apperley & Parind B. Patel (2014) Rapid initial response of myeloma hyperammonemic encephalopathy to L-ornithine-L-aspartate and dexamethasone therapy, Leukemia & Lymphoma, 55:1, 198-200
Anthony Pham, John L. Reagan, Jorge J Castillo; Plasma Cell Myeloma Causing Hyperammonemia Associated with High Inpatient Mortality. Blood 2012; 120 (21): 5002. doi: https://doi.org/10.1182/blood.V120.21.5002.5002
Murtaza G, Lu H, Faqah A, Konowitz N, Kuruvilla A, Adhikari S. Multiple Myeloma-Induced Hyperammonemic Encephalopathy. J Hematol. 2017;6(1):29-31. doi:10.14740/jh322e
How to Cite
“A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab” (2023) Mediterranean Journal of Hematology and Infectious Diseases, 15(1), p. e2023012. doi:10.4084/MJHID.2023.012.
Copyright (c) 2022 Mauro Passucci, Francesca Fazio, Maria Teresa Petrucci
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
